References
- Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20: 3644–3650.
- Katz A, Zalewsky P. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. Br J Canc 2003; 89 (2): 15–18.
- Wang ML, Yung WA, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-Fluorouracil-resistant brain metastases from brain cancer. Am J Clin Oncol 2001; 24 (4): 421–424.
- Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III tudy of temozolomide versus dacarbazine in the treatments of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–166.
- Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22: 2101–2107.
- Biasco G, Pantaleo MA, Casadei S. treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 2001; 345: 621–622.
- Dvorak J, Melichar B, Zizka J, Hadzi-Nikolov D, Petera J. Complete response of multiple melanoma brain metastases after treatment with temozolomide. Onkologie 2004; 27:171–174.
- Abrey LE, Olson JD, Boutros DY, et al. A phase II study of temozolomide for recurrent brain metastases. Proc Am Soc Clin Oncol 2000; 19:166a (abstract).
- Christodoulou C, Bafaloukos D, Kosmidis P, et al. Temozolomide (TMZ) in patients with brain metastases from solid tumors. A Hellenic Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 2000; 19:171a (abstract).
- Korones D, Benita-Weiss 0, Lechtler L, et al. A phase I study of temozolomide (temodar) and escalating doses of oral VP16 for adults with recurrent malignant gliomas. Proc Am Soc Clin Oncol 2001; 20:A2055 (abstract).
- Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003; 8: 69–75.
- Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. IMAJ 2003; 5: 833–834.
- Fujiwara K, Katsuyuki K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M. Dramatic effect of ZD 1839 (“Iressa”) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003; 40: 73–76.
- Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch Jr TJ, Penson RT. Living as a cancer surpriser: a doctor tells his story. Oncologist 2003, 8: 108–122.
- Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD139 (Iressa) in the brain. Ann Oncol 2003; 14: 656–658.
- Cappuzzo F, Ardizzoni A, Soto-Parra H. Epidermal growth factor recepror targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41: 227–231.
- Cappuzzo F, Calandri C, Bartolini S, Crinò L. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 2003; 89:246–247.
- Ochs JS. Rationale and clinical basis for combining gefitinib (Iressa, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 2004; 58:941–949.
- Haringhuizen A, van Tinteren H, Vaessen HF, Baas P, van Zandwijk N. Gefitinib as a last treatment option for nonsmall-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 2004; 15:786–792.